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Abstract: Increasing lines of evidence indicate that NKG2D, an activating receptor of natural killer 
(NK) and CD8
+
 T cells, plays an important role in immune responses against HIV-1. Through its abil-
ity to recognize a diverse array of ligands (NKG2DLs) induced by cell ‘stress’ such as viral infection, 
NKG2D delivers activating and co-stimulatory signals resulting in cytotoxicity and release of cytoki-
nes. Therefore, HIV-1 and other viruses have evolved clever mechanisms to counteract NKG2D-
dependent immune responses. While, on one hand, the HIV-1 Vpr protein up-regulates NKG2DLs ex-
pression by activating the DNA damage response (DDR) pathway, other viral proteins (Nef and Vif) have developed the 
capacity to reduce NKG2DLs expression levels. In addition, recent evidences suggest that HIV-1-infected CD4
+
 T cells 
may release NKG2DLs, particularly MICA, in soluble form, a phenomenon that has the potential to down-modulate 
NKG2D on circulating lymphocytes and allow evasion of NKG2D-mediated immune responses. Indeed, despite being 
controversial, lower NKG2D expression was found on both NK and CD8
+
 T cells in HIV-1-infected patients. This review 
discusses recent advances in the understanding of how HIV-1 affects the NKG2D/NKG2DLs system, with a special focus 
on virus-induced release of soluble NKG2DLs and its functional implications for the immune surveillance of the infected 
host. 
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1. INTRODUCTION 
The natural-killer group 2 member D (NKG2D) is one of 
the most studied immune receptors of the last decade. Sev-
eral distinct ligands for NKG2D have been identified, all up-
regulated in infected, transformed, and, more in general, dis-
tressed cells. By a plethora of in vitro and in vivo studies, the 
crucial role of NKG2D in the immune control of viral infec-
tions and cancer has been clearly demonstrated. As discussed 
here, it has recently become evident that NKG2D may take 
an important part in the capacity of cytotoxic lymphocytes to 
recognize and kill HIV-1-infected CD4
+
 T cells. The present 
review especially examines recent results suggesting that 
soluble NKG2DLs are released by HIV-1-infected cells and 
can down-modulate NKG2D as a means of viral immune 
escape. The possibility that HIV-1 uses soluble NKG2DLs to 
subvert NKG2D-mediated immune surveillance opens the 
way to novel therapeutic strategies and deserves to be further 
explored. This discussion speculates on the latest findings 
and is conceived to provide ideas for future studies. 
2. AN OVERVIEW OF NKG2D AND ITS LIGANDS 
2.1. The NKG2D Receptor 
NKG2D is a potent activating receptor constitutively ex-
pressed in humans by all natural killer (NK) cells and CD8
+
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T cells, and by subsets of γδ T cells, NKT cells, and 
CD4
+
 T cells [1]. Being widely expressed on cells of both 
innate and adaptive immune system, NKG2D has been in-
volved in the regulation of immune responses during infec-
tion, neoplastic transformation as well as autoimmunity [1, 
2].  
NKG2D is a dimeric, type II transmembrane protein de-
void of signaling properties but constitutively associated 
with the DAP10 adaptor molecules (four for each receptor 
homodimer). Ligand binding by NKG2D results in DAP10 
tyrosine phosphorylation followed by recruitment and activa-
tion of the p85 regulatory subunit of the phosphatidylinositol 
3-kinase (PI3-K) and the growth factor receptor-bound pro-
tein 2 (Grb2). The NKG2D pathway and its impact on im-
mune cells have been intensely studied as reported in a num-
ber of reviews [1-3]. In general, the activating signal deliv-
ered by NKG2D triggers cytotoxicity and cytokine produc-
tion in NK cells, thus functioning as a major activating 
pathway for NK-cell mediated elimination of transformed 
and infected cells [4]. On the other hand, NKG2D engage-
ment on CD8
+
 T cells is not sufficient to induce cytotoxicity 
or cytokine production [5], with the exception of CD8
+ 
T 
cells derived from tumors or inflamed tissues that respond to 
NKG2D triggering in the absence of other stimuli [6, 7]. In 
most cases, NKG2D engagement functions as co-stimulus 
for CD8
+
 T cells, thus amplifying TCR-mediated activation 
and enhancing proliferation, cytotoxicity and cytokines re-
lease [8-10]. In addition, increasing lines of evidence indi-
cate that NKG2D regulates the differentiation of both NK 
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[11] and CD8
+ 
T cells [9, 12]. Finally, some studies reported 
NK cell-mediated killing of activated T cells via NKG2D, 
suggesting that the receptor exerts a negative regulation over 
T-cell responses that might be relevant for the limitation of 
undesirable immune activation and for the maintenance of 
lymphocyte homeostasis [13, 14]. 
2.2. The NKG2D Ligands (NKG2DLs) 
A very peculiar aspect that distinguishes NKG2D from 
other activating receptors is its capacity to bind a diverse 
array of ligands (generically defined as NKG2DLs) rather 
than one or two. The NKG2DLs are self-proteins structurally 
similar to the MHC class I molecules, albeit not associated 
with β-microglobulin or peptide, that fall in two families: the 
MHC-class-I-related sequence A (MICA) and B (MICB) 
protein family and the cytomegalovirus UL16-binding pro-
tein family consisting of six members (ULBP1-6) [15]. De-
spite the fact that all NKG2DLs share an MHC-class-I-like 
α1α2 domain that binds NKG2D, they vary considerably in 
their sequence and receptor binding affinity, and they either 
are anchored to the cell membrane via a glycosylphosphati-
dylinositol (GPI) molecule (ULBP1-3, 6) or display trans-
membrane (TM) domains and cytoplasmic tails of variable 
length (MICA, MICB, ULBP4-5). In addition, NKG2DLs 
show polymorphisms in their coding sequences, particularly 
MICA for which more than 80 allelic variants exists, and 
promoters [16, 17]. Very recently, the MICA variant most 
frequently expressed in Caucasians, MICA*008, that has 
shorter TM and cytoplasmic regions and is synthesized as a 
free soluble protein, was shown to be located at the plasma 
membrane through the post-translational acquisition of a GPI 
anchor [18]. The NKG2DLs diversity should represent an 
advantage for the human immune system fighting against 
rapidly evolving viruses and cancers, as discussed in previ-
ous reviews [19, 20]. In fact, expression of NKG2DLs is low 
or absent in most normal cells but it is up-regulated in virus-
infected and cancer cells that, as a consequence, become 
exposed to NKG2D-mediated immune surveillance. The 
biosynthesis of NKG2DLs is practically regulated at any 
stage: transcription, RNA stability, translation, protein an-
terograde transport, protein stability, and soluble protein 
release from the cell. A thorough overview of this complex 
regulation has been recently published [20]. In brief, the 
transcription of NKG2DLs genes is dependent on transcrip-
tion factors such as NF-κB, Sp1 and E2F [21-24] and on 
epigenetic mechanisms (e.g. histone acetylation) that regu-
late the accessibility of the transcription machinery to 
NKG2DL promoter sequences [25]. In addition, a large body 
of evidence supports a key role of the DNA Damage Re-
sponse (DDR) pathway, specifically of the DNA damage 
sensor kinases ATM (ataxia telangiectasia-mutated) and 
ATR (ATM and Rad3-related), in the induction of 
NKG2DLs expression in transformed and infected cells as 
well as in normal cells undergoing mitosis or other physio-
logical processes in which DDR is activated [26]. Both en-
hanced transcription and mRNA stabilization have been pro-
posed as mechanisms of NKG2DLs up-regulation resulting 
from activation of the DDR pathway, but the molecular de-
tails await elucidation. It is clear though, that NKG2DL 
mRNAs can be detected in healthy cells devoid of cell-
surface ligands and that post-transcriptional mechanisms 
exist to prevent NKG2DL translation and expression in 
healthy cells. In particular, cellular microRNAs (miRNAs) 
that are either constitutively expressed or induced, were 
shown to bind NKG2DL mRNAs and repress their transcrip-
tion [27-29]. On the other hand, some miRNAs targeting 
MICA mRNA are degraded upon lipopolysaccharide activa-
tion, indicating that NKG2DLs expression can be derep-
ressed by infections or inflammation by elimination of cou-
pled miRNAs [30]. At the protein stage, NKG2DLs can be 
negatively regulated by ubiquitination followed by rapid 
degradation, as demonstrated for MULT1, the murine 
ortholog of ULBP1 [31]. Additional mechanisms affecting 
NKG2DLs stability and intracellular trafficking exist, often 
subverted in transformed and virally infected cells (these 
latter are examined later in this review). Finally, the mecha-
nisms underlying the release of soluble NKG2DLs have been 
intensively studied in recent years and are discussed below in 
a separate section. 
Overall, NKG2DLs expression involves the coordinated 
effect of several pathways. Interestingly, there are stimuli 
that specifically induce only one ligand or that are effective 
in one cell type but not another. As a general rule, which 
ligand is up-regulated and to what extent reflect not only 
NKG2DLs diversity and polymorphism, but also the nature 
of the stress stimulus, the type of distressed cell and its tissue 
microenvironment. 
3. SHEDDING OF SOLUBLE NKG2D LIGANDS AND 
ITS IMPACT ON NKG2D-MEDIATED IMMUNO-
SURVEILLANCE 
The capacity of cells to release soluble forms of 
NKG2DLs (sNKG2DLs) in the extracellular milieu was ini-
tially discovered in patients with gastrointestinal cancers 
[32], but later observed also in other solid tumors and in a 
variety of hematological malignancies and autoimmune dis-
orders [33], as well as in physiologic contexts such as preg-
nancy [34] and antigen-mediated activation of T cells [35]. 
Soluble MICA, sMICB, and sULBP2 proteins have been 
found in the sera of cancer patient, and basically every MIC 
and ULBP ligand has been detected in soluble form in cul-
ture supernatants of either cancer cells, transfected cell lines 
or activated T cells, indicating that any NKG2DL can poten-
tially be released in the extracellular environment. The re-
lease of sNKG2DLs reduces the cell-surface ligand density 
and, at the same time, allows circulation of cell-free ligands 
with a potentially intact capacity to bind their cognate recep-
tor. This phenomenon may thus have important functional 
consequences for NKG2D-mediated responses and it has 
been intensively investigated in the last decade. 
Three distinct mechanisms for the generation and release 
of sNKG2DLs have been described [15, 36, 37]. First, the 
ectodomain of NKG2DLs can be released from the cell 
membrane upon cleavage by matrix metalloproteinases 
(MMPs), cellular endopeptidases that primarily target cell 
membrane proteins to regulate tissue remodeling, leukocyte 
migration and inflammatory processes [38]. In particular, 
two MMPs, MMP9 and MMP14, and some members of ‘a 
disintegrin and metalloproteinase’ (ADAM) family (i.e. 
ADAM9, ADAM10, ADAM15, and ADAM17), have been 
implicated in the cleavage of MICA, MICB, and ULBP2 on 
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the basis of studies with tumor cell lines of various origin in 
which metalloproteinase (MP) inhibitors and siRNA-
mediated down-regulation of individual MPs have been used 
[37]. Overall, these studies also suggest that an MP is more 
or less effective at shedding a given NKG2DL depending on 
the enzyme activation status, which may vary considerably 
in different tumor cells. 
The second mechanism involves the release of full-length 
ligands in exosomes, which are vesicles of endosomal origin 
loaded with a variety of cellular proteins and provided with 
immunomodulatory functions. Some studies suggested that 
the truncated MICA*008 variant and ULBP3 are primarily 
released in exosomes, while longer MICA variants, MICB, 
and ULBP2, are shed by MP-mediated cleavage [39, 40]. 
Nonetheless, basically all MIC and ULBP proteins were de-
tected in purified exosomes in a number of studies [41-43]. 
A reconciling model has been proposed for which most 
NKG2DLs can be released either by proteolytic shedding or 
via exosomes, with the first mechanism being favored when 
cells express activated MP enzymes and ligands undergo 
secondary modification that increase their susceptibility to 
MP-mediated cleavage (e.g. palmitoylation and conforma-
tional changes mediated by the endoplasmic reticulum disul-
phide isomerase protein 5 -ERP5- or heat shock 70kDa pro-
tein 5 -HSPA5/GRP78-) [15]. 
A third mechanism generating sNKG2DLs is based on 
alternative RNA spicing. Indeed, a splice variant transcript 
of ULBP4 was shown to generate a soluble protein secreted 
in the cell supernatant [44]. However, this is at present the 
only example and it is not known whether other NKG2DLs 
can be expressed as free soluble molecules from alternative 
splicing of their mRNAs. 
Importantly, the accumulation of sNKG2DLs in the se-
rum of patients with various tumors correlates with disease 
progression, metastasis, and poor survival [37]. Indeed, sev-
eral studies have demonstrated that shedding of sNKG2DLs 
has detrimental effects on NKG2D-mediated immune re-
sponses. First of all, several reports showed that, by blocking 
MPs expression or activity, tumor cells express higher cell-
surface NKG2DLs levels and become more susceptible to 
NKG2D-dependent lysis [45-49]. Second, a number of stud-
ies demonstrated that sNKG2DLs present in patient plasma 
samples or cell culture supernatant can down-regulate 
NKG2D on NK and T cells, resulting in receptor internaliza-
tion/degradation and reduced cytotoxicity of these cells 
against NKG2DL
+
 targets [40, 50-53]. Moreover, in some 
cancer patients, elevated serum levels of sNKG2DLs, par-
ticularly sMICA, were associated with low NKG2D expres-
sion on circulating NK and CD8
+
 T cells [49, 53]. Interest-
ingly, some studies reported that NKG2DLs within 
exosomes are more effective at down-modulating NKG2D 
than their counterparts cleaved in soluble form [39, 40], pos-
sibly due to the presence of multiple molecules anchored on 
exosomal membranes. On the other hand, one report showed 
that tumor-derived NKG2DL
+
 exosomes down-modulated 
NKG2D mainly through TGF-β [41]. In addition, an oppo-
site outcome was reported for NKG2DL
+
 exosomes released 
from dendritic cells (DCs) that could directly activate NK 
cells ex vivo [43]. Therefore, it is evident that the effect of 
exosome-bound NKG2DLs on the expression and function 
of their cognate receptor is determined by the overall set of 
exosomal molecules provided with immunomodulatory ac-
tivities. 
Despite all evidences here described, some reports have 
failed to confirm that sNKG2DLs, specifically sMICB and 
sULBP2 derived from transfected cell lines, down-modulate 
NKG2D on cells exposed in vitro [46, 55]. In addition, 
NKG2D expression was not found consistently reduced in all 
patients with elevated serum levels of sMICA [56, 57]. 
Hence, some aspects of the immune response regulation by 
sNKG2DLs are still not fully elucidated. For a more com-
prehensive understanding, some issues should be taken into 
account and further investigated. First, some cell-bound 
NKG2DLs (i.e. MICA, MICB, and ULBP2) are apparently 
more effective than their secreted conterparts at decreasing 
NKG2D expression on in vitro exposed NK or CD8+ T cells 
[54, 55]. Second, different ligands may vary in their capacity 
to engage and down-modulate NKG2D, as recently reported 
[58]. Third, secondary modifications of cell-bound, cleaved, 
and exosome-bound ligands that are important for their func-
tional interaction with the receptor may not necessarily be 
recapitulated by in vitro experimental systems. One last very 
important aspect is the dual effect (NKG2D up- or down-
regulation) that cytokines secreted in the in vivo microenvi-
ronment may have on NKG2D expression independently of 
ligand engagement [59]. 
4. ROLE OF THE NKG2D/NKG2DLS SYSTEM IN 
THE CONTROL OF VIRAL INFECTIONS 
Increased NKG2DLs expression has been reported in 
human cells infected with HIV-1 and several other viruses, 
including human cytomegalovirus (HCMV), adenovirus, 
Epstein-Barr virus (EBV), hepatitis C virus (HCV), vesicular 
stomatitis virus (VSV), measles virus (MV), respiratory syn-
cytial virus (RSV), and influenza virus (FluA) [60-67]. At 
present, how viruses induce NKG2DLs is poorly understood. 
In principle, viral infection can up-regulate NKG2DLs tran-
scription indirectly by triggering stress and signaling path-
ways that support activation of NF-κB and other transcrip-
tion factors implicated in ligand gene expression. These con-
nections, however, have not been experimentally proven, as 
yet. Notably, some components, if not all, of the DDR path-
way that controls NKG2DLs expression, are generally acti-
vated during infection as part of the host cell response 
against viral genome integrity and replication [68]. On the 
other hand, to favor their own replication, viruses have 
evolved the capacity to regulate the DDR pathway by either 
stimulating or inhibiting some of its components [69, 70]. 
Actually, a link between NKG2DLs up-regulation and DDR 
pathway activation has been clearly demonstrated only for 
HIV-1 (described later in details), but one may speculate that 
this link will be extended to other viruses by future studies. 
With the mounting evidence that viral infection up-regulates 
ligands for an activating receptor of cytotoxic lymphocytes, 
it is expected that viruses have evolved means to prevent 
expression of these ligands at post-transcriptional levels. 
Indeed, this seems to be the case for some viruses including 
HIV-1. By means of bioinformatics and functional studies, 
the group of O. Mandelboim has demonstrated that herpes 
viruses (specifically, HCMV, EBV, and Kaposi’s sarcoma-
associated herpesvirus or KSHV) and polioma viruses (i.e. 
Soluble NKG2D Ligands in HIV-1 Infection Current Drug Targets, 2016, Vol. 17, No. 1    57 
JC and BK) encode miRNAs that target the 3’ untranslated 
region (3’UTR) of cellular mRNAs coding for MICB and 
ULBP3, respectively, thus impeding ligand translation and, 
as a consequence, NK-cell mediated lysis of infected cells 
[61, 71, 72]. This mechanism is highly specific and suggests 
that individual NKG2DL may have a precise role in a given 
virus-host cell interaction. To prevent expression of 
NKG2DLs, viruses use other mechanisms beyond miRNAs 
targeting that are based on virally encoded proteins generi-
cally called ‘immunoevasins’. For example, HCMV encodes 
two proteins that bind and sequester in the endoplasmic re-
ticulum (ER)/Golgi compartments distinct NKG2DLs: 
UL16, that targets MICB, and ULBP1, 2, 6, and UL142, that 
targets both MICA (but not MICA*008) and ULBP3 [73-
76]. Analogously, the adenovirus E3/19K protein sequesters 
intracellularly newly synthesized MICA and MICB mole-
cules [77]. In addition, the U21 protein encoded by the hu-
man herpes virus-7 (HHV-7) relocalize ULBP1 to lysosomal 
compartments [78]. Finally, the K5 protein of KSHV pro-
motes intracellular retention of MICA upon ubiquitination of 
its cytoplasmic tail [79]. Importantly, in all these instances, 
the activity of viral immunoevasins resulted in impairment of 
NKG2DLs cell-surface expression and protection from 
NKG2D-mediated killing by NK cells. One last example is 
HIV-1, which was recently found to encode two immunoe-
vasins acting at different steps of NKG2DLs biogenesis (see 
below). 
5. IMPACT OF HIV-1 ON NKG2DLS EXPRESSION 
5.1. NKG2DLs Up-Regulation by HIV-1 
The very first evidence that HIV-1 up-regulates 
NKG2DLs was obtained in our laboratory [62]. Specifically, 
by flow cytometric analysis, we observed that the cell-
surface expression of ULBP1 and ULBP2, but not MICA, 
was induced on HIV-infected primary CD4
+
 T cells at day 5 
post-infection with the HIV-1 NL4-3 strain and cell activa-
tion (that is necessary to allow viral replication). These re-
sults were confirmed by others and linked to the capacity of 
NK cells to kill HIV-infected T cell targets through NKG2D 
activation [80]. An important study by Fogli et al. showed 
that ex vivo expanded HIV-infected CD4+ T cells derived 
from HIV
+
 patients, express ULBP2 and low levels of 
ULBP1 and ULBP3, hence are susceptible to lysis by 
autologous NK cells in a manner that mainly depends on 
NKG2D activation [81]. More recently, we found that HIV-1 
infection also up-modulates MICA and MICB expression 
soon after stimulation (day 3 post-activation) of resting 
CD4
+
 T lymphocytes previously exposed to the virus if com-
pared with non-exposed control cells [82]. Of note, T cell 
activation itself, a prerequisite for HIV-1 replication, induces 
NKG2DLs transient expression with a dual kinetics: the MIC 
proteins are up-regulated first, with a pick at day 3 post-
activation, while ULBPs are induced later and reach a 
maximum at day 5 [14]. The fast kinetics of MICs up-
regulation explains why the effect of HIV-1 on these ligands 
was not observed when only late post-activation time points 
(5-7 days) were investigated [62, 80, 81, 83]. 
One of the accessory proteins of HIV-1, Vpr (viral pro-
tein R), induces a G2 cell-cycle arrest through a multistep  
 
process that involves binding to the cellular cullin-ring E3 
ubiquitin ligase (DDB1-CUL4A) and induction of the DDR 
pathway via ATR activation [84]. Therefore, based on the 
fact that NKG2DLs can be induced upon activation of the 
DDR pathway, two groups independently investigated 
whether the HIV-1 Vpr protein, expressed alone or in the 
context of virally infected cells, was capable of up-regulating 
NKG2DLs [85, 86]. By comparing primary CD4
+
 T cells 
infected with wild type (wt) vs Vpr-deficient HIV-1 (ΔVpr), 
both studies clearly demonstrated that HIV-1-induced up-
regulation of NKG2DL, specifically ULBP2, was dependent 
on the presence of the Vpr protein. Apparently, only ULBP2 
was strongly up-regulated on the membrane of infected cells, 
although experimental evidences indicate that Vpr increases 
various NKG2DLs at the transcriptional levels (i.e. ULBP1 
and ULBP2, but also, to a much lesser extent, ULBP3, 
MICA, and MICB). Thus, it is possible that these studies 
missed the precise time points at which NKG2DLs other 
than ULBP2 are up-modulated on the membrane of infected 
T cells. The effect of Vpr on NKG2DL expression was main-
tained when the protein was expressed individually but it 
was impaired by mutations abrogating the capacity to recruit 
the E3 ubiquitin ligase complex and to activate the ATR 
kinase or when the activity of cellular ATR was inhibited. 
Taken together, these data indicate that Vpr up-regulates 
NKG2DLs through recruitment of the E3 ubiquitin ligase 
complex and ATR-mediated activation of the DDR pathway 
(Fig. 1). The same molecular interactions are also required 
for Vpr capacity to arrest infected cells in G2, a cell-cycle 
phase enabling efficient viral replication, therefore 
NKG2DLs up-regulation might be secondary to the G2 ar-
rest. Work performed in E. Cohen laboratory also demon-
strated that Vpr associated with non-infectious HIV-1 parti-
cles as well as extracellular soluble Vpr, can up-regulate 
ULBP2 upon transduction of bystander T cells [86, 87], a 
phenomenon that should predictably contribute to CD4
+
 T 
cell loss by NKG2D-mediated cytotoxic responses against 
bystander uninfected ULBP2
+
 cells. The fine mechanistic 
details of Vpr-induced up-regulation of NKG2DLs yet need 
to be elucidated. In this context, it would be interesting to 
investigate the role of NF-κB and Sp1 transcription factors, 
which have been implicated in both NKG2DL genes expres-
sion [21, 22] and in Vpr-induced transactivation of the HIV-
1 long terminal promoter region [88]. 
Finally, it would be important to investigate whether, 
during HIV-1 infection, other factors besides Vpr can con-
tribute to DDR triggering and, consequently, to NKG2DLs 
up-regulation. One of these factors may be the DNA damage 
sensor kinase ATM, which becomes activated during HIV-1 
DNA integration (Fig. 1) [89]. Moreover, a study by Norman 
et al. showed that the apolipoprotein B-editing complex 3G 
(APOBEC3G or A3G), a cellular antiviral factor that inhibits 
HIV-1 replication by deaminating cytidine residues to 
uridine, activates the DDR pathway resulting in increased 
NKG2DLs expression and sensitization of infected T cells to 
NK-cell mediated killing (Fig. 1) [90]. This interesting study 
suggests a novel anti-HIV-1 function for A3G beyond direct 
damaging of the viral genome, which consists in the initia-
tion of a cellular ‘suicide mission’ meant to clear infected 
cells through lysis by NK cells. 
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5.2. NKG2DLs Down-Regulation by HIV-1 
As a countermeasure for NKG2DLs up-regulation, HIV-
1 has developed means to inhibit cell-surface ligand expres-
sion.  
In particular, work from our group has shown that the vi-
ral Nef protein has the ability to lower the cell-surface ex-
pression of MICA, ULBP1, and ULBP2, with a stronger 
effect on the latter molecule, and to reduce NKG2D-
dependent killing by NK cells (Fig. 1) [62]. This function of 
Nef was active in the context of viral replication, because 
NKG2DLs up-regulation was further enhanced in primary 
CD4
+
 T cells infected with a Nef-deficient HIV-1 if com-
pared to the expression of cells infected with wt virus, as 
observed by our own and other groups [62, 82, 90]. The 
HIV-1 Nef protein has the capacity to interfere with the cell-
surface expression of several membrane proteins including 
CD4 and CXCR4 virus receptors, antigen presenting mole-
cules (e.g. MHC-I), and co-stimulatory molecules (e.g. 
CD28) with important functional consequences for viral 
pathogenesis and in vivo spread [91]. To do so, Nef acts as a 
multifunctional adaptor that misdirects cellular proteins 
away from the plasma membrane through increased inter-
nalization, retention within intracellular compartments, and, 
in some cases, re-routing to lysosomes for degradation [92]. 
Mutagenesis-based studies have established that the capaci-
ties of Nef to interact with cellular cofactors and to down-
regulate CD4 and MHC-I require specific amino acid resi-
dues and are genetically separable. However, none of several 
Nef mutants tested (e.g. defective for the down-modulation 
of CD4 and/or MHC-I and for association with SH3 do-
mains) lost the capacity to reduce NKG2DLs cell-surface 
expression [62], suggesting that Nef uses a distinct, not yet 
identified mechanism to target NKG2DLs. Moreover, Nef 
might use different mechanisms to down-regulate each indi-
vidual NKG2DL, since all Nef variants analyzed had a 
stronger activity on ULBP2 if compared to MICA and 
ULBP1, and patient-derived Nef variants were active on 
MICA and ULBP2, but not on ULBP1. A larger screening of 
mutated and patient-derived Nef proteins for their activity on 
different NKG2DLs and a thorough analysis of the molecu-
lar mechanisms involved are clearly needed. 
A second HIV-1 protein that contrasts NKG2DLs expres-
sion is the viral infectivity factor (Vif). Vif interacts with a 
Cullin 5-ElonginB/C E3 ligase to target cellular A3G for 
degradation, hence overcoming antiviral host restriction im-
posed by A3G. By decreasing A3G levels, Vif also counter-
acts the enhancement of NKG2DLs expression due to A3G-
mediated activation of the DDR pathway, as demonstrated 
by Norman and colleagues [90]. By comparing T cells in-
 
Fig. (1). A schematic model of the NKG2D/NKG2DLs system in the context of HIV-1 infection. (Left) In CD4
+
 T lymphocytes infected 
with HIV-1, the DNA damage response pathway (DDR) is triggered by the Vpr viral protein, by activated APOBEC3G (A3G), and by viral 
DNA integration, resulting in increased NKG2DLs mRNA levels and cell-surface NKG2DLs expression (1). Consequently, infected cells 
become susceptible to NKG2D-mediated recognition and killing by cytotoxic lymphocytes (NK cells and CD8
+
 cytotoxic T lymphocytes or 
CTLs). (Right) The cell-surface NKG2DLs expression is restrained by two HIV-1 immunoevasins, Nef (2) and Vif (3), this latter by induc-
ing A3G degradation and limiting DDR activation. In addition, activated cellular metalloproteinases (MPs) cleave NKG2DLs so that their 
ectodomain is released in soluble form (sNKG2DLs) in the extracellular milieu (4). Lower NKG2DLs expression results in reduced activa-
tion of NKG2D
+
 cytotoxic lymphocytes. Circulating sNKG2DLs can bind to their cognate receptor causing its systemic down-regulation on 
NK cells and CTLs and, thus, compromising the immunological competence of HIV-1-infected patients. 
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fected with HIV-1 wt or defective for the expression of Vif, 
Vpr, or both viral proteins, Norman et al. demonstrated that, 
similarly to Nef, Vif prevented the optimal Vpr-mediated up-
regulation of NKG2DLs. By means of Vif mutants, the 
authors also showed that the negative effect of Vif on 
NKG2DLs expression specifically depends on its capacity to 
bind and degrade A3G. 
In sum, the capacities of Nef and Vif to restrain 
NKG2DLs expression render HIV-1-infected cells less sus-
ceptible to NKG2D-dependent immune recognition. These 
activities are not very efficient, because higher NKG2DL 
levels are found on CD4
+
 T cells infected with wt virus (i.e. 
expressing both Nef and Vif) if compared to non-infected 
cells [62, 90]. However, reduced NKG2DL expression sums 
up with other immune evasion strategies that HIV-1 has 
evolved to escape from recognition and killing by NK cells 
(e.g. down-regulation of NTB-A, NKp44L and PVR) [93-95] 
and CD8
+
 T cells (e.g. MHC-I down-regulation by Nef) [96]. 
It is reasonable to envision that, all together, these escape 
mechanisms will result in a less efficient recognition and 
destruction of virus-producing cells by cytotoxic lympho-
cytes and, consequently, in a significant increase of HIV-1 
replication and spread in the infected host. 
5.3. Soluble NKG2DLs Shedding by HIV-1 
The eventuality that viral infection, analogously to tu-
morigenic transformation, could determine the release of 
sNKG2DL was investigated in a study on HIV-1-infected 
patients [83]. Nolting et al., found higher levels of sMICA in 
the plasma of patients with chronic untreated HIV-1 infec-
tion if compared to healthy HIV-negative individuals or 
HIV-1-infected subjects who spontaneously controlled viral 
replication (controllers). Conversely, aviremic HIV-1-
infected patients treated with highly active antiretroviral 
therapy (HAART) had an intermediate phenotype, displaying 
levels of sMICA that were significantly higher if confronted 
with controllers but not with HIV-negative controls. In-
creased sMICA in untreated HIV-1-infected patients was 
accompanied by an up-regulation of some MMPs (MMP2 
and MMP7, but not MMP1, MMP9 and the ERP5 enzyme) 
in CD4
+
 T lymphocytes, supporting the hypothesis that cir-
culating sMICA was released via MMP-mediated shedding 
from CD4
+
 T cells exposed to HIV-1. In line with this 
model, in vitro infected CD4+ T cells expressed higher 
amounts of MICA mRNA and also, when treated with 
MMP-inhibitors, elevated cell-surface MICA levels. Moreo-
ver, in all HIV-infected patients, both HAART-treated and, 
even more, untreated subjects, with the exception of control-
lers, NK cells had a reduced NKG2D expression and defec-
tive NKG2D-dependent functions (degranulation and activa-
tion) compared with controls. The authors of this study con-
clude that, like some tumors, HIV-1 may suppress NKG2D-
dependent functions of NK cells by enhancing MMP-
mediated secretion of sMICA. 
In our laboratory, we further investigated this aspect by 
means of in vitro infected T cells and patient-derived sam-
ples. First, we demonstrated that HIV-1 infection of primary 
CD4
+
 T cells results in increased expression and release in 
the culture medium of the three NKG2DLs tested, namely 
MICA, MICB, and ULBP2 [82]. We also showed that incu-
bation with a broad spectrum MMP-inhibitor resulted in a 
further increase of ligands on the membrane of HIV-1-
infected T cells and decreased ligand accumulation in the 
culture medium, but had irrelevant effects in control non-
infected T cell cultures. Then, by treating plasma samples 
with detergent in order to release NKG2DLs from macro-
complexes, we disclosed the presence of sMICA, sMICB, 
and sULBP2 in the plasma of several healthy individuals, in 
line with previously reported evidence that ligand expression 
and shedding can occur in normal cells undergoing physiol-
ogic processes, such as activation, proliferation, and differ-
entiation [35, 97]. Notwithstanding, untreated patients with 
chronic HIV-1 infection displayed increased plasma levels of 
sMICA (and a similar, not statistically significant trend for 
sULBP2) and reduced NKG2D expression on circulating NK 
and CD8
+
 T cells if compared to HAART-treated patients or 
healthy donors. Intrapatient analysis before and after 
HAART treatment, clearly demonstrated that effective anti-
viral therapy reduced plasma sMICA and sULBP2 levels and 
strongly increased NKG2D expression on both NK and 
CD8
+
 T cells in HIV-1-infected patients. These results sug-
gest that, in patients with chronic HIV-1 infection, the accu-
mulation of sNKG2DLs released by infected CD4
+
 T cells 
causes systemic down-regulation of the cognate receptor on 
effector cells, but HAART has the potential to avoid such 
immune dysfunction. Finally, we demonstrated that, indeed, 
sNKG2DLs in patients’ plasma had the capacity to down-
regulate NKG2D on NK and CD8
+
 T cells and to impair 
NKG2D-mediated cytotoxicity of NK cells. This last set of 
experiments was performed by incubating peripheral blood 
mononuclear cells (PBMCs) of HIV-negative donors with 
the plasma of untreated HIV-1-infected patients, immunode-
pleted or not of sMICA or sULBP2, or with the plasma of 
healthy individuals devoid of sNKG2DLs. However, for 
some plasma/NK cells combinations investigated we were 
not able to ascribe to sMICs and sULBP2 the observed 
down-regulation of NKG2D or inhibition of NK cells cyto-
toxicity, which could be explained by the presence of other 
not tested NKG2DLs or distinct soluble factors regulating 
NKG2D. 
Taken together, results from Nolting and colleagues and 
from our laboratory support a model in which HIV-1 induces 
infected CD4
+
 T cells to release sNKG2DLs, at least sMICA, 
as a means to evade NKG2D-mediated immune recognition 
and, simultaneously, to ‘detune’ the NKG2D receptor on 
circulating cytotoxic lymphocytes (Fig. 1). In both studies, 
the release of sNKG2DLs by HIV-1 seems to rely on the 
function of cellular MMPs, which is in line with the estab-
lished role of these enzymes in ligand shedding from various 
tumor cells [37] and with the reported MMP up-modulation 
during HIV-1 infection [98]. 
However, various aspects of the NKG2DLs shedding by 
HIV-1 are still obscure or very preliminary. Some controver-
sial points that deserve extensive investigation are discussed 
here below: 
i) Not all HIV-1-infected patients consistently presented 
high amounts of circulating sMICA or sULBP2. A simplistic 
explanation for the absence of sMICA or sULBP2 in the 
plasma of several untreated HIV-1-infected patients analyzed 
[82, 83, 99, and our unpublished results] can be that these 
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individuals express ligand alleles not responsive to virally 
induced shedding. Interestingly, in a previous study it was 
shown that, despite the great majority of healthy individuals 
express MICA on the surface of activated T cells, sMICA is 
released in only 40% to 70% of subjects, depending on the 
time point analyzed [35]. On the other hand, T cells derived 
from healthy donors always released sMICB upon antigenic 
stimulation [35] and very high sMICB levels can be found in 
the plasma of some healthy individuals [82]. Therefore, the 
responsiveness of various ligand alleles to shedding may 
vary among individuals independently of viral infection. 
Further investigation is needed to evaluate whether and how 
the polymorphisms of NKG2DLs can influence ligand ex-
pression and shedding in both healthy and HIV-infected in-
dividuals. 
ii) There is no relationship between sMICA or sULBP2 
levels and viral load or CD4
+
 T cell count. Despite the fact 
that accumulation of sMICA or sULBP2 occurred in some 
HIV-infected individuals, no relationship was found between 
the amounts of individual ligands and CD4
+
 T cell count or 
viral load [82]. Therefore, the accumulation of sNKG2DL 
could not be directly linked to viral replication, at least at the 
single time point analyzed. 
iii) NKG2D expression levels do not show an inverse 
correlation with sNKG2DL amounts. The level of NKG2D
 
expression in HIV-1-infected patients or healthy donors did 
not show an inverse correlation with the amount of each 
ligand tested (our unpublished observation), which could be 
due to the fact that accumulation of sNKG2DLs and 
sNKG2DL-induced receptor down-regulation occur tran-
siently and follow different kinetics or, alternatively, that 
reduced NKG2D expression results from the combined in-
crease of multiple ligands or other regulatory factors not yet 
evaluated. Adding to the overall complexity, the capacity of 
NK and T cells to respond to NKG2D engagement is highly 
variable among humans and individual NKG2D-mediated 
immune responses are tuned to optimal ligand doses that 
may vary considerably [100]. Moreover, ligand alleles or 
receptor haplotypes may influence the individual NKG2D 
responsiveness by determining qualitative effects (e.g. bind-
ing affinity). Finally, it is plausible that the concentration of 
sNKG2DLs in those tissues and secondary lymphoid organs 
where HIV-1 replication preferentially occurs could be a lot 
higher than that detected in the plasma. 
6. EXPRESSION AND FUNCTION OF NKG2D DUR-
ING HIV-1 INFECTION 
Several ex vivo studies investigated the expression and 
function of the NKG2D receptor in cells derived from HIV-
1-infected patients and healthy donors, often coming to dis-
cordant conclusions. 
Some studies have shown that NK cells from viremic 
HIV-1-infected patients maintain normal NKG2D expression 
[99, 101-103] and also conserved NKG2D-mediated cytotox-
icity as measured by a redirected killing assay in one report 
[101]. On the contrary, lower NKG2D expression on NK 
cells from viremic patients if compared with healthy donors 
was described in other studies [82, 83, 104], including one in 
which dysfunctional receptor down-regulation in response to  
 
stimulation was observed [83]. Even more controversial is 
the expression of NKG2D on NK cells from HAART-treated 
aviremic patients, which was found either maintained [82, 
101], decreased [83], or increased [105] by comparison with 
healthy individuals. Moreover, either normal [83], higher 
[105], or lower NKG2D expression [99] was described for 
NK cells from HIV-1 controllers as compared to healthy 
subjects. 
Overall, the diversified pattern of NKG2D expression 
and function in NK cells from a given group of patients sug-
gests that other variables beyond the clinical, virological, and 
immunological parameters that have been taken into consid-
eration so far, crucially controls the receptor in these cells. It 
is very likely that individual variations and polymorphisms 
of the NKG2DL/NKG2D system may account for incongru-
ences within the same group of patients. In this matter, longi-
tudinal studies may possibly bring to more homogenous re-
sults. Indeed, as mentioned earlier, the analysis of the same 
patients before and after HAART initiation disclosed that 
effective viral suppression resulted in a dramatic increase in 
NKG2D expression on NK and CD8
+
 T cells associated with 
a drop of circulating sNKG2DLs [82]. 
As to CD8
+
 T cells, the expression and function of 
NKG2D on these cells in the context of HIV-1 infection re-
mains largely unexplored. In two pilot studies, lower 
NKG2D expression on CD8
+
 T cells from untreated HIV-1-
infected patients compared to healthy donors was observed 
[82, 99]. Lecuroux et al. also showed that both total and 
HIV-specific CD8
+
 T cells expressed lower NKG2D levels 
in different groups of HIV-infected patients (with primary 
infection, untreated, and HAART-treated) but not in patients 
with spontaneous viral suppression. These data indicate that 
defective NKG2D expression may contribute to impaired 
cytotoxic responses of CD8
+
 T cells against HIV-1 as well as 
other pathogens. Further investigation is needed, especially 
since a recent study clearly underscored the importance of 
the NKG2D pathway in anti-HIV-1 CD8
+
 T cell responses 
[106]. Specifically, Zloza and colleagues showed that 
NKG2D co-stimulation during priming was capable of rescu-
ing the recall capability of CD4-unhelped memory CD8
+
 T 
cells in both experimental mice models and ex vivo human 
cells, including CD8
+
 T cells derived from HIV-1-infected 
individuals with low CD4
+
 T cell counts. The augmented co-
stimulation through NKG2D resulted in the suppression of 
the transcription factor T-box expressed in T cells (T-bet) 
and in the recovery of IL-2 and IFN-γ production and cyto-
lytic responses, thus rescuing CD8
+
 T cell responses from 
chronic HIV-infected patients to resemble those associated 
with HIV
+
 long term non progressor patients. 
7. THERAPEUTIC IMPLICATIONS 
Recent results here overviewed indicate that NKG2DLs 
shedding by HIV-1 can provoke NKG2D down-regulation 
and impair the responses of NK cells and, presumably, CD8
+
 
T cells, thus compromising the immunological competence 
of infected patients. Therefore, understanding the mecha-
nisms through which the virus induces the release of 
sNKG2DLs and, subsequently, developing therapeutic 
strategies to suppress shedding of these molecules, may offer 
a substantial benefit for HIV-infected patients. 
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In principle, an ideal therapeutic strategy should consist 
in maximizing the expression of NKG2DL on HIV-1-
infected cells and, at the same time, impairing ligand shed-
ding and NKG2D down-regulation on cytotoxic lympho-
cytes. Several anti-cancer therapies that are currently in pre-
clinical and clinical development, combine drugs that up-
regulate NKG2DLs (e.g. conventional chemotherapeutic 
drugs, DNA damaging agents, histone deacetylase inhibi-
tors), with agents that induce NKG2D expression (e.g. IL-15, 
anti-TGF-β monoclonal antibody) or inhibit sNKG2DLs 
shedding (e.g. the multi-target kinase inhibitor Sorafenib) 
[107]. Following an analogous combinatorial strategy, the 
association of agents boosting the NKG2D/NKG2DLs sys-
tem with antiretroviral therapy or HIV-1-specific therapeutic 
vaccination, should be considered to maximize the effects of 
such approaches. Indeed, immunotherapy with IL-15, IL-7 
and other common γ-chain signaling cytokines that up-
regulate NKG2D expression, is being evaluated in conjunc-
tion with HAART or HIV-1 vaccine [108]. Moreover, al-
though still highly experimental, the use of MMP inhibitors 
that can block sNKG2DLs shedding has been proposed as 
adjuvant for anti-HIV therapy [98]. 
8. CONCLUDING REMARKS AND PERSPECTIVES 
A better and more comprehensive understanding of the 
biochemistry and biological functions of individual 
NKG2DLs is clearly needed. In recent years, novel 
NKG2DL polymorphisms and secondary modifications have 
been regularly discovered and the list of stimuli that induce 
NKG2DL expression and of mechanisms that regulate ligand 
biogenesis has grown constantly. Despite intensive investiga-
tion, several aspects regarding NKG2DL regulation are 
poorly understood, as yet, including the molecular mecha-
nisms of ligand shedding, secretion, and exosome-mediated 
release, and their consequences for NKG2D function. In ad-
dition, it has become increasingly clear that the NKG2D re-
ceptor itself is under very stringent control. Indeed, the 
NKG2D-NKG2DL interaction has the potential to either 
activate or desensitize NK cells or CD8
+
 T cells, possibly 
depending on the nature of the ligand (i. e. genotype, iso-
form, secondary structure, cell/exosome-bound vs soluble) 
and on its relative abundance and persistence. 
Along with the yet elusive aspects of the 
NKG2D/NKG2DLs system, clearly much work remains to 
be done in order to elucidate the fine mechanisms through 
which HIV-1 subverts this system to affect NKG2D-
mediated immune surveillance. In future studies on 
sNKG2DLs shedding, it will be important to identify which 
NKG2DL genotypes are affected by the virus, also extending 
the analysis to ligands that have not been investigated, as yet. 
Furthermore, deciphering which cellular MPs mediate 
sNKG2DLs release by infected cells and how these enzymes 
are activated by the virus will certainly be of value. In fact, 
HIV-1 may induce MPs expression and function directly 
within infected cells or by the establishment of a state of 
chronic immune activation in the infected host. On the other 
hand, antiretroviral drugs can target MMPs [109], therefore 
it will be interesting to investigate whether low/undetectable 
plasma levels of sNKG2DLs and normal NKG2D expression 
in treated HIV-1-infected patients can be ascribed to 
HAART-mediated impairment of MMPs activity and to what 
extent. 
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